Ae­glea re­places CEO as com­pa­ny is set to cut more em­ploy­ees, change strat­e­gy

Many com­pa­nies have been re­cent vic­tims of the bud­get axe. And an Austin, TX biotech is no ex­cep­tion.

Ae­glea Bio­Ther­a­peu­tics an­nounced ear­li­er this week that the com­pa­ny was un­der­tak­ing a cor­po­rate re­struc­tur­ing in an at­tempt to fo­cus on now-lead can­di­date AGLE-177, cur­rent­ly in de­vel­op­ment for pa­tients with ho­mo­cystin­uria, a rare in­her­it­ed dis­ease where a pa­tient can­not process the amino acid me­thio­n­ine. The re­org re­duces the com­pa­ny’s em­ploy­ee num­bers fur­ther, now close to a 25% cut so far in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER